As of 2026-04-03, the Intrinsic Value of 10X Genomics Inc (TXG) is 3.95 USD. This TXG valuation is based on the model Discounted Cash Flows (EBITDA Exit 5Y). With the current market price of 22.33 USD, the upside of 10X Genomics Inc is -82.30%.
The range of the Intrinsic Value is 3.66 - 4.84 USD
Based on its market price of 22.33 USD and our intrinsic valuation, 10X Genomics Inc (TXG) is overvalued by 82.30%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | (13.33) - (3.94) | (6.57) | -129.4% |
| DCF (Growth 10y) | (2.26) - (7.67) | (3.79) | -117.0% |
| DCF (EBITDA 5y) | 3.66 - 4.84 | 3.95 | -82.3% |
| DCF (EBITDA 10y) | 4.06 - 6.14 | 4.59 | -79.4% |
| Fair Value | -1.70 - -1.70 | -1.70 | -107.63% |
| P/E | (7.40) - (8.04) | (7.81) | -135.0% |
| EV/EBITDA | (2.37) - 3.76 | 0.41 | -98.2% |
| EPV | (13.49) - (16.85) | (15.17) | -167.9% |
| DDM - Stable | (2.56) - (6.95) | (4.76) | -121.3% |
| DDM - Multi | (0.20) - (0.42) | (0.27) | -101.2% |
| Market Cap (mil) | 2,852.66 |
| Beta | 1.98 |
| Outstanding shares (mil) | 127.75 |
| Enterprise Value (mil) | 2,378.69 |
| Market risk premium | 4.60% |
| Cost of Equity | 10.87% |
| Cost of Debt | 5.00% |
| WACC | 7.84% |